Trial Profile

A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 17 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs LN 145 (Primary) ; Aldesleukin; Cyclophosphamide; Fludarabine
Indications Adenocarcinoma; Carcinoma; Non-small cell lung cancer; Squamous cell cancer
Focus Registrational; Therapeutic Use
Sponsors Iovance Biotherapeutics

Most Recent Events

03 Nov 2025 According to an Iovance Biotherapeutics media release, the company will present additional data from the IOV-LUN-202 trial at an upcoming medical meeting in 2026.
03 Nov 2025 According to an Iovance Biotherapeutics media release, enrollment completion is expected in 2H 2026
03 Nov 2025 Interim results published in the Media Release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com